Flumatinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Flumatinib
Accession Number
DB11904
Description

Flumatinib has been used in trials studying the treatment of Myelogenous Leukemia, Chronic.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 562.601
Monoisotopic: 562.241642075
Chemical Formula
C29H29F3N8O
Synonyms
Not Available
External IDs
  • HH-GV678

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideThe therapeutic efficacy of Abaloparatide can be decreased when used in combination with Flumatinib.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Flumatinib.
CarbimazoleThe therapeutic efficacy of Carbimazole can be decreased when used in combination with Flumatinib.
FollitropinThe therapeutic efficacy of Follitropin can be decreased when used in combination with Flumatinib.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Flumatinib.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Flumatinib.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Flumatinib.
MethimazoleThe therapeutic efficacy of Methimazole can be decreased when used in combination with Flumatinib.
Parathyroid hormoneThe therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Flumatinib.
Potassium IodideThe therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Flumatinib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Flumatinib Mesylate95Y8L63NBC895519-91-2ZSASDYCFROUKTJ-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyridinylpyrimidines
Alternative Parents
Trifluoromethylbenzenes / Benzamides / Phenylmethylamines / Benzylamines / Benzoyl derivatives / Aminopyridines and derivatives / Aminopyrimidines and derivatives / N-methylpiperazines / Methylpyridines / Aralkylamines
show 10 more
Substituents
1,4-diazinane / Alkyl fluoride / Alkyl halide / Amine / Amino acid or derivatives / Aminopyridine / Aminopyrimidine / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
R4009Y24AI
CAS number
895519-90-1
InChI Key
BJCJYEYYYGBROF-UHFFFAOYSA-N
InChI
InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)
IUPAC Name
N-(6-methyl-5-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}pyridin-3-yl)-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide
SMILES
CN1CCN(CC2=CC=C(C=C2C(F)(F)F)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CC=CN=C3)=C(C)N=C2)CC1

References

General References
Not Available
PubChem Compound
46848036
PubChem Substance
347828237
ChemSpider
25069687
ChEMBL
CHEMBL3545413
ZINC
ZINC000068244727

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentAcute Lymphocytic Leukemia, Adult B-Cell / BCR-ABL1 Fusion Protein Expression1
3CompletedTreatmentCML, CML-CP,MMR,TKI1
2Active Not RecruitingTreatmentChronic Chronic myelogenous leukemia1
2Unknown StatusTreatmentChronic Chronic myelogenous leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0102 mg/mLALOGPS
logP3.43ALOGPS
logP3.66ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)11.21ChemAxon
pKa (Strongest Basic)7.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.17 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity152.3 m3·mol-1ChemAxon
Polarizability57.44 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 14:59 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates